Barcelona, Spain– INBRAIN Neuroelectronics, a clinical-stage neurotechnology firm pioneering graphene-based brain-computer interfaces (BCIs), has been awarded a €4 million grant from Spain’s Ministry of Industry and Tourism under the PERTE Chip initiative—a national strategy aimed at bolstering Spain’s microelectronics and semiconductor sector.
The funding will support INBRAIN’s continued development of precision BCIs that use graphene to decode and modulate brain activity in real time, with potential applications in treating neurological conditions such as Parkinson’s disease, epilepsy, and stroke-related impairments.
The PERTE Chip initiative (Strategic Project for Economic Recovery and Transformation of Microelectronics and Semiconductors) provisionally awarded a total of €53.2 million on May 5 to 37 projects across 11 autonomous communities. INBRAIN was selected for its high-impact potential at the intersection of advanced materials, intelligent computing, and next-generation healthcare.
“We are honored to receive this national support as part of Spain’s effort to lead in cutting-edge neurotechnology,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. “This grant enables us to accelerate the development of precision neurotechnologies while positioning Spain as a leader in deep tech healthcare innovation.”
INBRAIN’s neuroelectronic platform is built around biocompatible graphene interfaces capable of delivering adaptive neuromodulation with high spatial resolution. The company’s approach aims to provide safer and more precise alternatives to traditional neural implants, with the potential to extend into neuropsychiatric treatment in future applications.
Catalan government officials welcomed the announcement as a significant boost to regional and national innovation leadership. “INBRAIN represents exactly the kind of transformative technology we aim to support,” said Miquel Sàmper, Catalonia’s Minister of Business and Labor. “Their work not only advances medtech but also contributes to Spain and Europe’s strategic autonomy in critical technologies.”
The grant marks another milestone in INBRAIN’s mission to merge neuroscience, advanced materials, and AI-powered computing to reshape the treatment of complex neurological diseases.
